Overview

Useful For
Supporting the diagnosis of Lyme disease in conjunction with serologic testing

Specific indications including testing skin biopsies when a rash lesion is not characteristic of erythema migrans, and testing synovial fluid or synovium to support the diagnosis of Lyme arthritis

Testing Algorithm
The following algorithms are available in Special Instructions:

- Acute Tick-Borne Disease Testing Algorithm
- Meningitis/Encephalitis Panel Algorithm

Special Instructions

Method Name
Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization

NY State Available
Yes

Specimen

Specimen Type
Varies

Advisory Information
This assay does not detect Borrelia miyamotoi. If infection with this organism is suspected, order BMIYB / Borrelia miyamotoi Detection PCR, Blood or BMIYC / Borrelia miyamotoi Detection PCR, Spinal Fluid.

Necessary Information
Specimen source is required.

Specimen Required
Submit only 1 of the following specimens:

Specimen Type: Spinal fluid

Container/Tube: Sterile vial

Specimen Volume: 1 mL

Collection Instructions: Label specimen as spinal fluid.

Specimen Type: Synovialfluid
Container/Tube: Sterile vial

Specimen Volume: 1 mL

Collection Instructions: Label specimen as synovial fluid.

Specimen Type: Tissue (fresh only)

Sources: Skin or synovial biopsy

Container/Tube: Sterile container with normal saline

Specimen Volume: Approximately 4 mm(3)

Collection Instructions:
1. Submit only fresh tissue.
2. Skin biopsies:
   a. Wash biopsy site with an antiseptic soap. Thoroughly rinse area with sterile water. Do not use alcohol or iodine preparations. A local anesthetic may be used.
   b. Biopsy specimens are best taken by punch biopsy to include full thickness of dermis.
3. Label specimen with source of tissue.

Forms
If not ordering electronically, complete, print, and send a Microbiology Test Request (T244) with the specimen.

Specimen Minimum Volume
Spinal Fluid, Synovial Fluid: 0.3 mL
Tissue: NA

Reject Due To

<table>
<thead>
<tr>
<th></th>
<th>NA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemolysis</td>
<td>NA</td>
</tr>
<tr>
<td>Lipemia</td>
<td>NA</td>
</tr>
<tr>
<td>Icterus</td>
<td>NA</td>
</tr>
<tr>
<td>Other</td>
<td>Green-top (heparin) tube, yellow-top (ACD) tube, serum gel tube, blood, or plasma</td>
</tr>
</tbody>
</table>

Specimen Stability Information

<table>
<thead>
<tr>
<th>Specimen Type</th>
<th>Temperature</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Varies</td>
<td>Refrigerated (preferred)</td>
<td>7 days</td>
</tr>
<tr>
<td></td>
<td>Frozen</td>
<td>7 days</td>
</tr>
</tbody>
</table>

Document generated July 31, 2019 at 1:32pm CDT
Test Definition: PBORR
Lyme Disease PCR

Clinical and Interpretive

Clinical Information

Lyme disease is a multisystem and multistage tick-transmitted infection caused by spirochetal bacteria in the *Borrelia burgdorferi* sensu lato (Bbsl) complex.(1) Nearly all human infections are caused by 3 Bbsl species; *B burgdorferi* sensu stricto (hereafter referred to as *B burgdorferi*) is the primary cause of Lyme disease in North America, while *B afzelii* and *B garinii* are the primary causes of Lyme disease in Europe. In 2012, *B mayonii* has been identified as a less common cause of Lyme disease in the upper Midwestern United States.(2,3) This organism has only been detected in patients with exposure to ticks in Minnesota and Wisconsin and has not been detected in over 10,000 specimens from patients in other states including regions of northeast where Lyme disease is endemic.

Lyme disease is the most commonly reported tick-borne infection in Europe and North America, causing an estimated 300,000 cases in the United States each year, and 85,000 cases in Europe.(4,5) The clinical features of Lyme disease are broad and may be confused with various immune and inflammatory disorders. The classic presenting sign of early localized Lyme disease caused by *B burgdorferi* is erythema migrans (EM), which occurs in approximately 80% of individuals. Other early signs and symptoms include malaise, headache, fever, lymphadenopathy, and myalgia. Arthritis, neurological disease, and cardiac disease may be later stage manifestations. Erythema migrans has also been seen in patients with *B mayonii* infection, but diffuse rashes are more commonly reported.(2) The chronic skin condition, acrodermatitis chronicum atrophicans, is also associated with *B afzelii* infection.

The presence of EM in the appropriate clinical setting is considered diagnostic for Lyme disease and no confirmatory laboratory testing is needed. In the absence of a characteristic EM lesion, serologic testing is the diagnostic method of choice for Lyme disease.(6) However, serology may not be positive until 1 to 2 weeks after onset of symptoms, and may show decreased sensitivity for detection of infection with *B mayonii*. Therefore, detection of Bbsl DNA using PCR may be a useful adjunct to serologic testing for detection of acute disease. PCR has shown utility for detection of *Borrelia* DNA from skin biopsies of Lyme-associated rashes and also be used to detect *Borrelia* DNA from synovial fluid and synovium biopsies. Less commonly, *Borrelia* DNA can be detected in cerebrospinal fluid.(7) Lyme PCR should always be performed in conjunction with FDA-approved serologic tests, and the results should be correlated with serologic and epidemiologic data and clinical presentation of the patient.(8) The Mayo Clinic Lyme PCR test detects and differentiates the main causes of Lyme disease in North America (*B burgdorferi* and *B mayonii*) and Europe (*B afzelii* and *B garinii*).(2,7)

Reference Values

Negative

Interpretation

A positive result indicates the presence of DNA from *Borrelia burgdorferi*, *B mayonii*, *B afzelii*, or *B garinii*, the main agents of Lyme disease.

A negative result indicates the absence of detectable target DNA in the specimen. Due to the clinical sensitivity limitations of the PCR assay, a negative result does not preclude the presence of the organism or active Lyme disease.

Cautions

Serologic tests are recommended for diagnosis of Lyme disease. PCR may play an adjunctive role, but may not detect *Borrelia burgdorferi* DNA from cerebrospinal fluid (CSF) in cases of active or chronic disease. The presence of inhibitory substances may also cause a false-negative result. If clinical features of illness are highly indicative of Lyme neuroborreliosis, serologic testing on CSF is warranted. PCR test results should be used as an aid in diagnosis and not considered diagnostic by themselves. These results should be correlated with serologic and epidemiologic
data and clinical presentation of the patient.

Testing of CSF by PCR in patients with suspected Lyme neuroborreliosis should be requested only on patients with positive *B. burgdorferi* antibody in serum confirmed by Western blot assay (LYWB / Lyme Disease Antibody, Immunoblot, Serum) and with abnormal CSF findings (elevated protein and WBC >10 cells/high-power field).

Concurrent infections with multiple tick-borne pathogens, including *Ehrlichia muris eauclairensis*, *Anaplasma phagocytophilum*, *Babesia microti*, and *B. miyamotoi* (a relapsing fever *Borrelia*) have been reported in United States, and consideration should be given to testing for other pathogens if clinically indicated.

This assay detects most members of the *Borrelia burgdorferi* sensu lato complex, including *B. andersonii*, *B. americana*, and *B. bissettii*, which have been rarely detected in humans. Detection of DNA from these organisms would be reported as an atypical result and prompt additional laboratory testing to further identify the DNA present. The sensitivity of this assay for detecting these organisms has not been determined.

This assay also detects some members of the *B. burgdorferi* sensu lato (Bbsl) complex that are not considered to be human pathogens, but may be found in ticks and other animals. Therefore, this assay should not be used to test nonhuman specimens.

**Supportive Data**

The following validation data supports the use of this assay for clinical testing.

**Analytical Sensitivity/Limit of Detection (LoD):**

The lower LoD is approximately 300 to 1,000 genomic copies/mL in cerebrospinal fluid (CSF), tissue, blood, and synovial fluid.

**Accuracy/Diagnostic Sensitivity and Specificity:**

Spiking studies of whole organism in fresh tissue, synovial fluid, and CSF (spiked near the approximate LoD) showed 100% recovery.

**Analytical Specificity:**

No PCR signal was obtained from the extracts of 22 bacterial, viral, parasitic, and fungal isolates that can cause symptoms similar to Lyme disease including: *Rickettsia rickettsii*, *R. typhi*, *Ehrlichia canis*, *Babesia microti*, *Plasmodium falciparum*, *P. vivax*, *Bartonella henselae*, *Bartonella quintana*, Herpes simplex virus, and *Toxoplasma gondii*. Relapsing fever borreliae (including *Borrelia miyamotoi*) are also not detected with this assay.

**Precision:**

Interassay precision was 100% and intra-assay precision was 100%.

**Reference Range:**

The reference range for this assay is negative. This assay is only to be used for patients with a clinical history and symptoms consistent with Lyme, and must be interpreted in the context of serologic tests, which are the gold standard for diagnosis of Lyme disease. This test should not be used to screen asymptomatic patients.

**Reportable Range:**

This is a qualitative assay, and the results are reported as negative or positive for targeted *B. burgdorferi*, *B. afzelii*, *B.
**Test Definition: PBORR**

**Lyme Disease PCR**

*garinii, or B mayonii.*

### Clinical Reference


### Performance

#### Method Description

Nucleic acid is extracted from clinical specimens using the automated MagNA Pure LC instrument system. The extract is then transferred to individual wells of a 96-well plate for amplification. The LightCycler is an automated instrument that amplifies and monitors the development of target nucleic acid (amplicon) after each cycle of PCR. The DNA target for PCR assay is the 283-bp plasminogen-binding protein gene (*OppA2*), which is present at a frequency of 1 copy per organism in all 4 confirmed pathogenic species of the *Borrelia burgdorferi* sensu lato genogroup (*B burgdorferi* sensu stricto, *B afzelii, B garinii* and *B mayonii*). A specific base pair DNA target sequence is amplified by PCR. The detection of amplicon is based on fluorescence resonance energy transfer (FRET), which utilizes 1 hybridization probe with a donor fluorophore, fluorescein, at the 3’ end, and a second hybridization probe with an acceptor fluorophore, LC-Red 610, at the 5’ end. When the target amplicon is present, the LC-Red 610 emits a measurable and quantifiable light signal at a specific wavelength. Presence of the specific organism nucleic acid may be confirmed by performing a melting curve analysis of the amplicon. Using features of the melting curve analysis, the assay primers and specific hybridization probes are able to detect and differentiate *B burgdorferi* sensu stricto from *B mayonii, B afzelii, and B garinii*, although the melting curve analysis cannot differentiate between *B afzelii* and *B garinii*. Each assay run can be completed within 60 minutes.(Cockerill FR, Uhl FR: Applications and challenges of real-time PCR for the clinical microbiology laboratory. In Rapid Cycle Real-Time PCR. Edited by U Reischl, C Wittwer, F Cockerill. Springer, NY 2002)

### PDF Report

No
Day(s) and Time(s) Test Performed
Monday through Saturday (June through November)
Monday through Friday (December through May)

Analytic Time
1 day

Maximum Laboratory Time
4 days

Specimen Retention Time
1 week

Performing Laboratory Location
Rochester

Fees and Codes

Fees
- Authorized users can sign in to Test Prices for detailed fee information.
- Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
- Prospective clients should contact their Regional Manager. For assistance, contact Customer Service.

Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information
87476
87798 x 2
87999 (if appropriate for government payers)

LOINC® Information

<table>
<thead>
<tr>
<th>Test ID</th>
<th>Test Order Name</th>
<th>Order LOINC Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>PBORR</td>
<td>Lyme Disease PCR</td>
<td>In Process</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Result ID</th>
<th>Test Result Name</th>
<th>Result LOINC Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>SRC71</td>
<td>Specimen Source</td>
<td>31208-2</td>
</tr>
<tr>
<td>23635</td>
<td>B. burgdorferi PCR</td>
<td>In Process</td>
</tr>
<tr>
<td>38288</td>
<td>B. mayonii PCR</td>
<td>82474-8</td>
</tr>
<tr>
<td>38289</td>
<td>B. garinii/B. afzelii PCR</td>
<td>82472-2</td>
</tr>
<tr>
<td>38323</td>
<td>Lyme CSF Comment</td>
<td>59464-8</td>
</tr>
</tbody>
</table>